Welcome to our dedicated page for PARK HA BIOLOGICAL TECHNOLOGY SEC filings (Ticker: BYAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Park Ha Biological Technology Co., Ltd.'s SEC filings document the regulatory record of a Cayman Islands foreign private issuer with operating subsidiaries that sell Park Ha skincare and cosmetic products in China. Current reports on Form 6-K cover Nasdaq listing compliance, board changes, shareholder voting matters and amendments to its memorandum and articles.
The company's filings also describe its capital structure, including Class A ordinary shares, Class B ordinary shares with higher voting rights, warrants issued in public offerings, securities purchase agreements, placement agency arrangements and Form F-1 registration statement disclosures. These records connect financing activity and share-capital matters to BYAH's public-company governance and reporting obligations.
Park Ha Biological Technology Co., Ltd. CTO Li Xinyu has reported initial ownership on a Form 3. The filing shows 937.5 Class A Ordinary Shares are held indirectly through Changxin International Limited Partnership, where Ms. Li is a limited partner. A footnote states these shares were acquired on October 11, 2022.
Park Ha Biological Technology Co., Ltd. director Yu Xiaozhong filed an initial Form 3 to report insider status with respect to BYAH. The filing lists Yu as a director and confirms that, at the time of this report, no insider transactions or derivative positions are reported.
Park Ha Biological Technology Co., Ltd. filed an initial insider ownership report for CFO Zhu Xiaoyan. The filing shows 2,500 Class A Ordinary Shares held indirectly through Changxin International Limited Partnership. A footnote states these 2,500 Class A Ordinary Shares were acquired on October 11, 2022, with Ms. Zhu described as a limited partner of that partnership.
Park Ha Biological Technology Co., Ltd. director and CEO Zhang Xiaoqiu filed an initial Form 3 reporting her beneficial ownership in the company. She is identified as a director, officer and ten percent owner.
The filing shows indirect ownership of 381,000 Class B Ordinary Shares, held through Xiaoqiu Holdings Limited, where she is the sole shareholder and director. A footnote states that these 381,000 Class B Ordinary Shares were acquired on October 11, 2022, and the Form 3 records this existing position rather than reporting a new market transaction.
Park Ha Biological Technology Co., Ltd. director Sheng Qixiong has filed an initial statement of beneficial ownership as a reporting person. This Form 3 lists him as a director but shows no reported transactions, acquisitions, or derivative positions at the time of the filing.
Park Ha Biological Technology Co., Ltd. reported that Li Wang resigned as a director of the company, effective March 16, 2026. The company states that her resignation was not due to any disagreement with its operations, policies, or procedures.
The report is signed by Chief Executive Officer and Chairperson Xiaoqiu Zhang, indicating the change has been formally approved and acknowledged at the highest leadership level.
Park Ha Biological Technology Co., Ltd. reports that it has regained compliance with Nasdaq’s minimum bid price requirement. Nasdaq notified the company that its Class A ordinary shares closed at or above $1.00 per share for 10 consecutive business days from February 20 through March 5, 2026.
Meeting this threshold satisfies Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market, and Nasdaq has closed the matter. This removes the immediate risk that the company’s shares could be delisted for bid-price non-compliance.
Park Ha Biological Technology Co., Ltd. files its annual Form 20-F, outlining operations conducted entirely through PRC subsidiaries in the beauty and skincare industry and detailing extensive China-related regulatory risks.
The company highlights cybersecurity, data, CSRC filing and HFCAA audit-inspection risks that could ultimately lead to trading prohibitions or delisting, as well as controls on cross-border cash transfers and dividend payments. As of October 31, 2025, there were 296,488 Class A ordinary shares and 381,000 Class B ordinary shares issued and outstanding.
The filing also describes reliance on third-party manufacturers’ formulas, a highly competitive beauty market, dependence on a few major customers and franchise expansion, and structural risks tied to variable interest entities used to control certain beauty salons in China.
Park Ha Biological Technology Co., Ltd. plans a 1-for-50 reverse stock split of its Class A and Class B ordinary shares. The change has already been approved by shareholders and the board, and is expected to become effective on February 20, 2026, with trading beginning on a split-adjusted basis that day.
Immediately before the reverse split, the company has 104,768,362 ordinary shares issued and outstanding, reflecting its recent follow-on offering and related warrant exercises. After the reverse split, the share count is expected to be adjusted to 2,095,368 ordinary shares. Fractional shares will not be issued; any fractional amounts will be rounded up to the nearest whole share. The company does not anticipate other material changes to the terms of its securities in connection with this action.
Park Ha Biological Technology Co., Ltd. plans a 1-for-50 reverse stock split effective February 20, 2026, with trading to begin on a split-adjusted basis that day, subject to satisfying Nasdaq Operations notice requirements.
To align with this change, the company amended its Memorandum of Association to reduce authorized share capital from USD 3,000,000.00 divided into 150,000,000,000 ordinary shares of par value US$0.00002 each (120,000,000,000 Class A and 30,000,000,000 Class B) to 3,000,000,000 ordinary shares of par value US$0.001 each (2,400,000,000 Class A and 600,000,000 Class B), using the same 1-for-50 ratio as the issued and outstanding shares.
Shareholders approved the reverse split at an extraordinary meeting on December 26, 2026, and the Board of Directors set the exact ratio on January 29, 2026.